CXCR4 and neoplasm: In addition, the inoculation of 5 × 106 cells, subcutaneously in recipient NSG mice, derived from disaggregated tumor cells obtained from CXCR4+ M5 SC tumors after the administration of 100 μg T22‐GFP‐H6‐FdU intravenous doses, for 2 consecutive days, leads to a reduction in tumor re‐initiation (as measured as diminished number and size of tumors) 10 days after the end of treatment, as compared to free oligo‐FdU‐treated or Buffer‐treated mice (Fig 5C and D).